Rationale for a vaccine using cellular-derived epitope presented by HIV isolates.

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• Cellular antigens like HLA and beta 2-microglobulin are incorporated into virion surfaces.
• A conserved epitope, R7V, derived from beta 2-microglobulin is presented across all human immunodeficiency virus (HIV) isolates.

Purpose of the Study:

• To identify and characterize the R7V epitope.
• To assess the potential of R7V as a target for developing a universal AIDS vaccine.

Main Methods:

• Blocking neutralizing capacity of a monoclonal antibody with a specific peptide.
• Developing an enzyme-linked immunosorbent assay (ELISA) using the identified peptide.
• Immunoprecipitation assays with purified anti-R7V antibodies.
• Immunization of rabbits with R7V and subsequent antibody analysis.

Main Results:

• A specific peptide was identified by blocking a monoclonal antibody targeting the R7V epitope.
• ELISA detected neutralizing antibodies against laboratory and primary HIV isolates in nonprogressor patients.
• Purified anti-R7V antibodies demonstrated concentration-dependent immunoprecipitation of all HIV isolates.
• Rabbit immunization with R7V induced HIV immunoprecipitating and neutralizing antibodies.
• Neither patient nor rabbit antibodies bound to host cells, and no autoimmune diseases were observed.

Conclusions:

• The R7V epitope is conserved across HIV isolates and elicits neutralizing antibodies.
• R7V is immunogenic and induces broadly reactive neutralizing and immunoprecipitating antibodies.
• R7V shows significant promise as a candidate for a universal AIDS vaccine due to its conserved nature and lack of autoimmune associations.